Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS
- PMID: 15768028
- DOI: 10.1038/nm1207
Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS
Abstract
Mutations in Cu/Zn superoxide dismutase (encoded by SOD1), one of the causes of familial amyotrophic lateral sclerosis (ALS), lead to progressive death of motoneurons through a gain-of-function mechanism. RNA interference (RNAi) mediated by viral vectors allows for long-term reduction in gene expression and represents an attractive therapeutic approach for genetic diseases characterized by acquired toxic properties. We report that in SOD1(G93A) transgenic mice, a model for familial ALS, intraspinal injection of a lentiviral vector that produces RNAi-mediated silencing of SOD1 substantially retards both the onset and the progression rate of the disease.
Similar articles
-
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.Nat Med. 2005 Apr;11(4):429-33. doi: 10.1038/nm1205. Epub 2005 Mar 13. Nat Med. 2005. PMID: 15768029
-
Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.Neurobiol Dis. 2006 Sep;23(3):578-86. doi: 10.1016/j.nbd.2006.04.019. Epub 2006 Jul 20. Neurobiol Dis. 2006. PMID: 16857362
-
Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.Methods Mol Biol. 2009;555:87-108. doi: 10.1007/978-1-60327-295-7_7. Methods Mol Biol. 2009. PMID: 19495690
-
[Amyotrophic lateral sclerosis: recent insights from transgenic animal models with SOD1 mutations].Rinsho Shinkeigaku. 2004 Nov;44(11):788-91. Rinsho Shinkeigaku. 2004. PMID: 15651292 Review. Japanese.
-
Silencing strategies for therapy of SOD1-mediated ALS.Neurosci Lett. 2017 Jan 1;636:32-39. doi: 10.1016/j.neulet.2016.07.059. Epub 2016 Aug 6. Neurosci Lett. 2017. PMID: 27507699 Review.
Cited by
-
Amyotrophic lateral sclerosis: update and new developments.Degener Neurol Neuromuscul Dis. 2012 Feb;2012(2):1-14. doi: 10.2147/DNND.S19803. Degener Neurol Neuromuscul Dis. 2012. PMID: 23019386 Free PMC article.
-
Progress on RNAi-based molecular medicines.Int J Nanomedicine. 2012;7:3971-80. doi: 10.2147/IJN.S31897. Epub 2012 Jul 26. Int J Nanomedicine. 2012. PMID: 22915846 Free PMC article. Review.
-
Sigma-1R agonist improves motor function and motoneuron survival in ALS mice.Neurotherapeutics. 2012 Oct;9(4):814-26. doi: 10.1007/s13311-012-0140-y. Neurotherapeutics. 2012. PMID: 22935988 Free PMC article.
-
Viral vectors and delivery strategies for CNS gene therapy.Ther Deliv. 2010 Oct;1(4):517-34. doi: 10.4155/tde.10.50. Ther Deliv. 2010. PMID: 22833965 Free PMC article. Review.
-
Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles.Cell Metab. 2018 Sep 4;28(3):400-414.e8. doi: 10.1016/j.cmet.2018.06.011. Epub 2018 Jul 12. Cell Metab. 2018. PMID: 30017354 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous